close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Medicis announces FDA approval of Loprox shampoo

Medicis announces FDA approval of Loprox shampoo

SCOTTSDALE, ARIZ., March 3, 2003 -- Medicis announced it has received approval of its New Drug Application from the FDA to market its new Loprox Shampoo (ciclopirox) 1%. Loprox Shampoo is the first and only prescription antifungal shampoo approved in the United States for the treatment of seborrheic dermatitis of the scalp, a common fungal infection.

Loprox Shampoo will have market exclusivity for a three-year period and is the subject of a pending patent application, which, if granted, could extend product exclusivity significantly. FDA approval of Loprox Shampoo obligates Medicis to pay to Aventis $5 million, representing the Company's last financial obligation to Aventis under terms of the Loprox transaction announced in fiscal year 1999. The Company expects to amortize this payment over a period of time consistent with the Loprox family of products.

Loprox Shampoo formulation is the most recent innovation to the Loprox family of antifungal products. The brand is the number one prescribed topical antifungal therapy in the specialties of dermatology and podiatry.

Loprox Shampoo is a prescription product and is available in a 120 ml size (NDC #99207-010-10). The Company expects product supply to be available within the next several months for shipping to wholesalers and anticipates promotion and sample distribution of Loprox Shampoo to physicians soon thereafter.

Seborrheic dermatitis is a common, chronic skin condition affecting approximately eight million Americans. Skin lesions caused by seborrheic dermatitis are typically located in areas abundant with sebum-producing glands including the scalp, face and upper trunk. Seborrheic dermatitis of the scalp is a common fungal infection characterized by inflammation, itching, and greasy scaling. This condition affects about 3% of the general population and can worsen if left untreated.

Medicis says Loprox Shampoo is an effective delivery system to treat seborrheic dermatitis of the scalp. A small percentage of people may experience side effects such as rash or other discomfort around the scalp.

Source: Medicis

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...